IRIS Institutional Research Information System - OPENBS Open Archive UniBS

QUIROS ROLDAN, Maria Eugenia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.073
AS - Asia 9.661
EU - Europa 7.497
SA - Sud America 2.072
AF - Africa 179
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 14
Totale 38.529
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.783
SG - Singapore 3.363
CN - Cina 3.120
UA - Ucraina 1.765
BR - Brasile 1.722
HK - Hong Kong 1.396
DE - Germania 1.370
IT - Italia 1.020
PL - Polonia 661
FI - Finlandia 588
GB - Regno Unito 555
VN - Vietnam 505
RU - Federazione Russa 460
TR - Turchia 390
IE - Irlanda 369
IN - India 316
FR - Francia 197
CA - Canada 143
AR - Argentina 125
BD - Bangladesh 112
SE - Svezia 107
MX - Messico 93
NL - Olanda 82
AT - Austria 73
EC - Ecuador 69
ID - Indonesia 67
ZA - Sudafrica 67
JP - Giappone 66
IQ - Iraq 63
ES - Italia 53
CZ - Repubblica Ceca 41
PK - Pakistan 35
BE - Belgio 32
AU - Australia 31
LT - Lituania 31
SA - Arabia Saudita 30
UZ - Uzbekistan 30
VE - Venezuela 30
CO - Colombia 29
IR - Iran 29
PY - Paraguay 25
CL - Cile 22
EG - Egitto 20
MA - Marocco 20
AE - Emirati Arabi Uniti 19
KE - Kenya 19
PE - Perù 19
UY - Uruguay 17
IL - Israele 16
JO - Giordania 15
EU - Europa 14
JM - Giamaica 14
AZ - Azerbaigian 12
BO - Bolivia 12
RO - Romania 12
TN - Tunisia 11
CH - Svizzera 10
DZ - Algeria 10
MU - Mauritius 10
HN - Honduras 8
KZ - Kazakistan 8
AM - Armenia 7
CR - Costa Rica 7
ET - Etiopia 7
HU - Ungheria 7
KR - Corea 7
PH - Filippine 7
PT - Portogallo 7
AL - Albania 6
LV - Lettonia 6
NP - Nepal 6
PA - Panama 6
BB - Barbados 5
BY - Bielorussia 5
KG - Kirghizistan 5
MK - Macedonia 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
EE - Estonia 4
MY - Malesia 4
OM - Oman 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
UG - Uganda 4
CI - Costa d'Avorio 3
DK - Danimarca 3
GE - Georgia 3
LB - Libano 3
LK - Sri Lanka 3
MD - Moldavia 3
NO - Norvegia 3
SI - Slovenia 3
TH - Thailandia 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CM - Camerun 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 38.500
Salva come PNG Salva come JPEG
Città #
Fairfield 2.267
Woodbridge 1.906
Ashburn 1.674
Singapore 1.627
Hong Kong 1.395
Jacksonville 1.335
Houston 1.259
Seattle 952
Cambridge 916
Wilmington 879
Ann Arbor 839
Chandler 730
Warsaw 653
Princeton 634
Beijing 606
Nanjing 467
New York 445
Los Angeles 375
Dublin 362
Istanbul 314
Helsinki 309
Munich 228
The Dalles 210
Des Moines 193
Nanchang 190
Dearborn 183
Moscow 181
Brescia 174
Buffalo 172
Ho Chi Minh City 171
São Paulo 169
Dallas 154
San Diego 137
Changsha 132
Shenyang 131
Milan 130
Shanghai 130
Hebei 124
Redondo Beach 121
San Francisco 115
Chicago 114
Jinan 113
Lancaster 99
Hanoi 93
London 92
Tianjin 91
Nuremberg 74
Turku 66
Jiaxing 65
Hangzhou 61
Tokyo 61
Kunming 59
Frankfurt am Main 51
Santa Clara 51
Rio de Janeiro 50
Toronto 50
Montreal 46
Guangzhou 45
Brooklyn 44
Zhengzhou 42
Belo Horizonte 40
Verona 39
Ningbo 38
Porto Alegre 36
Chennai 35
Mexico City 35
Atlanta 34
Denver 34
Jakarta 34
Johannesburg 34
Phoenix 33
Stockholm 33
Charlotte 32
Düsseldorf 32
Washington 32
Boardman 31
Brno 31
Poplar 31
Boston 30
Brasília 30
Brussels 30
Curitiba 30
Dong Ket 30
Kocaeli 29
Orem 29
Romola 29
Taizhou 29
Tashkent 28
Vienna 27
Haiphong 26
Lanzhou 26
Leawood 26
Manchester 25
Salt Lake City 25
Ardabil 24
Campinas 24
Quito 24
San Mateo 24
Lappeenranta 22
Rome 22
Totale 25.559
Salva come PNG Salva come JPEG
Nome #
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 395
The impact of antiretroviral therapy on iron homeostasis and inflammation markers in HIV-infected patients with mild anemia 279
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study 251
Modulation of Regulatory T-cell Subsets in Very Long-term Treated Aviremic HIV(+) Patients and Untreated Viremic patients 248
Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA "search and isolate" strategy in a hospital in Italy with hyperendemic MRSA 234
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz 219
Effectiveness of routine lumbar puncture in patients with HIV-associated Dementia (HAD) receiving suppressive antiretroviral treatment 211
Burden of Non-AIDS-Defining and Non-Virus-Related Cancers Among HIV-Infected Patients in the Combined Antiretroviral Therapy Era. 207
Cohort profile: Standardized management of antiretroviral therapy cohort (MASTER cohort) 204
The evolving burden of HIV infection compared with other chronic diseases in northern Italy 198
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 190
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 190
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 189
Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study 188
Hepatitis C infection influence on immune recovery in HIV-positive patients on successful HAART: The role of genotype 3 185
Prevalence of integrase strand transfer inhibitors (InSTIs) resistance mutations in InSTIs-naive and -experienced HIV-1 infected patients: a single Center experience 182
Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules. 177
Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy 177
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy 176
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study 172
Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. 169
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy 167
Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study 163
HIV-associated asymmetric lipodystrophy syndrome 162
Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012 160
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting 159
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 159
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. 158
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 157
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 157
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy 156
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 155
Evidence for antigenic selection of large granular lymphocytes in a patient with Wiskott-Aldrich syndrome 154
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. 153
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 152
Breast cancer among human immunodeficiency virus (HIV)-infected patients: the experience in Brescia, Northern Italy. 152
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. 151
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study 150
Lung cancer in HIV-infected patients: the experience in Brescia from 1999 to 2009 149
Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. 148
An enzyme-linked (alkaline phosphatase) oligonucleotide probe for the detection of serum hepatitis B virus DNA. 147
A population-based database to study malignancies in HIV-infected patients in the Local Health Unit of Brescia (Northern Italy), period 1999-2009 147
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 147
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. 146
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 146
Mapping the human genetic architecture of COVID-19 145
Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide 145
Bcl-2 expression is moderately correlated with long-term variability of CD4+ T-cell increase under successful highly active antiretroviral therapy 145
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 144
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. 144
Prevalence of non-B HIV-1 subtypes in North Italy and analysis of transmission clusters based on sequence data analysis 144
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients 143
Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living with HIV followed in a single center of Northern Italy 143
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 142
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 142
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 142
The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population 142
Peripheral loss of regulatory T cells and polyautoimmunity in an HIV-infected patient 142
Disseminated Histoplasmosis as AIDS-presentation. Case Report and Comprehensive Review of Current Literature 142
Immune response in children with COVID-19 is characterized by lower levels of T-cell activation than infected adults 142
HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir containing regimens 141
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 141
Comparison between the gold standard DXA with calcaneal quantitative ultrasound based-strategy (QUS) to detect osteoporosis in an HIV infected cohort 140
Impact of detectable human cytomegalovirus DNAemia on viro-immunologicaleffectiveness of HAART in HIV-infected patients naive to antiretroviral therapy 139
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? 138
A COPD case-finding program in a large cohort of HIV-infected persons 138
Lymphocyte homeostasis is maintained in perinatally HIV-infected patients after three decades of life 138
An outbreak of Serratia marcescens bloodstream infections associated with misuse of drug vials in a surgical ward 137
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. 137
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 136
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort 135
The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients 135
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. 134
Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients 134
Immune complex p24 antigen: a new prognostic marker in human immunodeficiency virus infection 133
Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy,1999-2009 133
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI 132
Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir 132
Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort 131
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study 130
Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART) 129
Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy 129
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). 128
Serum hepatitis B virus DNA detection with S- and C-region-directed probes 127
Different TCRBV genes generate biased patterns of V-D-J diversity in human T cells 127
The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study 127
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 126
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 126
A first update on mapping the human genetic architecture of COVID-19 125
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48 week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial 125
Polymorphic immune restoration syndrome after effective HAART 125
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir 125
Compassionate Use of Remdesivir for Patients with Severe Covid-19 125
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. 124
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 124
Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject with Solid Cancer in an Italian Multicenter Study 124
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 124
Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy 123
Elderly women with human immunodeficiency virus infection: is there an effect of the virus on neuropsychological prolife? 123
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 123
Totale 15.506
Salva come PNG Salva come JPEG
Categoria #
all - tutte 202.165
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 202.165
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.946 0 0 0 0 0 529 171 523 548 479 504 192
2021/20222.514 172 390 75 149 37 133 155 183 127 298 208 587
2022/20232.341 354 69 46 152 185 635 10 227 381 38 112 132
2023/20242.499 130 72 224 196 107 423 78 108 647 30 70 414
2024/20256.810 81 45 74 788 748 643 687 229 782 662 1.254 817
2025/20267.857 1.309 1.736 1.022 1.996 1.660 134 0 0 0 0 0 0
Totale 39.135